生物工艺在国际金融市场上遇到了日益暗淡的前景。三、四年前,投资者曾认为,任何一家大量与生物工艺有关的公司是显然可以获利的。事实上并非如此,尽管股东们还在继续同各商行合作,并且不断地进行投资,但是,由于这一行业在许多领域内不能实现商业的目的,不满和失望的情绪滋长起来,其原因和生物工艺本身一样复杂。 Biotechnology has encountered increasingly bleak prospects in international financial markets. Three or four years ago, investors had argued that any large number of biotechnology-related companies were clearly profitable. In fact, this is not the case. Although shareholders are continuing to cooperate with the firms and continue to invest, the causes and living conditions of the profession, as dissatisfaction and disappointment have grown due to the industry's inability to achieve commercial ends in many areas The process itself is as complicated as it is.